目的：探讨NK-92细胞对抑制Her2基因表达的卵巢癌细胞株SKOV-3细胞在体外及体内的杀伤活性。方法：靶向Her2的siRNA转染SKOV-3,筛选得到能稳定抑制Her2基因表达的细胞株SKOV-3/siRNA,并通过RT-PCR和免疫组织化学方法检测Her2基因抑制效果。应用 LDH 法检测 NK-92细胞对 SKOV-3、SKOV-3/siRNA 的杀伤活性。将 SKOV-3、SKOV-3/siRNA细胞接种到裸鼠皮下检测荷瘤情况,并比较NK-92细胞在各组治疗效果。结果：建立了稳定抑制Her2基因表达的细胞株SKOV-3/siRNA,Her2基因表达受到较强抑制。 NK-92在效靶比1：20时对 SKOV-3、SKOV-3/ siRNA 细胞杀伤率分别为(21.1±6.8)%和(45.5±8.9)%,差异有统计学意义(P<0.01)。接种SKOV-3/siRNA细胞实验组各时间点瘤体积均明显小于SKOV-3对照组(P<0.05~P<0.01)。 SKOV3/siRNA+ NK-92治疗组肿瘤质量均小于其他各组(P<0.05~P<0.01)。结论：NK-92细胞联合靶向Her2基因的siRNA可以抑制卵巢癌细胞株SKOV-3在体外和体内增殖,有望成为卵巢肿瘤治疗的新途径。%Objective:To explore the inhibition effects of NK-92 cells on the Her-2 gene expression in SKOV-3 cells in vitro and in vivo. Methods:The SKOV-3/siRNA cell line with persistent silencing the Her2 gene expression were established by the siRNA targeting Her2 gene transfecting into SKOV-3 cell line. The inhibition effects on Her2 gene mRNA expression were detected by RT-PCR and immunohistochemistry. The killing activity of NK-92 cells to SKOV-3 and SKOV-3/siRNA was detected by LDH. The tumor growth in the nude mice inoculated with SKOV-3 and SKOV-3/siRNA subcutaneously was observed. The effects of NK-92 cells on ovarian cancer in all cases were compared. Results:The SKOV-3/siRNA cell line with persistent silencing the Her2 gene expression was established, the Her2 gene expression was strong inhibited. The killing rates of NK-92 cells to SKOV-3 and SKOV-3/siRNA were(21. 1±6. 8)%and(45. 5±8. 9)% at 1:20 of the target ratio,respectively(P<0. 01). The tumor volume in mice inoculated with SKOV-3/siRN cells was significantly less than that in mice inoculated with ASKOV-3(P <0. 05 to P <0. 01),The tumor quality in mice treated with SKOV-3/siRN combined with NK-92 cells were significantly less than that in other mice(P<0. 05 to P<0. 01). Conclusions:NK-92 cells combined with siRNA targeting Her2 gene can inhibit the proliferation of the ovarian cancer cell line SKOV-3 in vitro and in vivo, which may become a new approach of ovarian cancer therapy.
展开▼
